Navigation Links
Regenicin™ to Present at the Rodman & Renshaw Healthcare Conference
Date:9/8/2010

NEW YORK, Sept. 8 /PRNewswire/ -- Regenicin™ (OTC Bulletin Board: WDST), a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin, will present at the Rodman & Renshaw Healthcare Conference held at the New York Palace Hotel, New York City from September 12-15, 2010.

Regenicin™ President Joe Connell will speak on Wednesday, September 15th at 11:15 am EDT to provide a status update on the company's Pipeline lead candidate PermaDerm™ as well as a general overview of Regenicin™, which went public in August.

About the Rodman Healthcare Conference

The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12th-15th. Henry M. Paulson, Jr., 74th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14th, 2010 at 5:30 PM.

Following Mr. Paulson's opening program, more than 200 public and private companies from around the world are expected to present to an audience of over 3,500 attendees.

About Regenicin™

Regenicin™, Inc. is a clinical-stage company developing next generation tissue-engineered skin substitute to restore healthy human skin in severe burn victims. Through a strategic alliance with Lonza Group Ltd., the company has licensed breakthrough technology that utilizes a patient's own skin to generate living, tissue-engineered skin that has been used in clinical trials to treat burn victims.

With over 2,000 cases annually involving burns covering over 50% of a patient's body, according to the American Burn Association, the potential United States market size for Regenicin™'s product is in excess of $3 billion annually. The product could also be used for a wide variety of other applications, including the treatment of patients with chronic wounds or use in reconstructive plastic surgery.

As the key component to Regenicin™'s PermaDerm™ tissue-engineered skin, its biomedical polymer is an important commercial product that could be used for a variety of other applications separately, including as protection for organs and tendons, as a carrier for hormones or medicines, as a protective healing agent for wounds, or as a carrier for stem cells, making this company one worth watching for investors. (www.regenicin.com).


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... Jupiter, FL (PRWEB) , ... June 23, 2017 , ... ... the award winning series, which is slated to air fourth quarter 2017. American Farmer ... Christian D.A. Hansen, a Danish pharmacist, founded Chr. Hansen in Denmark in 1874 ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that ... eastern Texas, is announcing the launch of a new charity drive to benefit women ... the United States reveal that an estimated 252, 710 new cases of invasive or ...
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is proud to report that ... Each year, research and information firm, Castle Connolly, releases their list of the most ... marks the 3rd time that Dr. Canales has been recognized by Castle ...
(Date:6/22/2017)... ... 2017 , ... Despite its pervasiveness, many physicians are unfamiliar with how best ... with clinical practice. Now, however, a timely review has been published in the ... etiology of NeuP and educating preclinical scientists on its diagnosis and choice of treatment. ...
Breaking Medicine News(10 mins):